focus -WSS

focus

author：explore 2025-10-02 22:27:03 - browse：67823

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Arc Institute generative AI designs new CRISPR systems

WSS

Venture capitalist Bob Kocher on the state of digital health

H5N1 bird flu outbreak: Second human case reported, in Michigan

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Second House panel advances two

Fentanyl is making it harder to start addiction treatment

Addressing health care workers' trauma can help fight burnout

hotspot

focus

explore

What does generative AI mean for health care? We asked experts

Anxious about a speech? A startup wants you to pop a minty cardiac drug

ChatGPT in medicine: STAT answers readers' burning questions

Investigation reveals sickle cell patients pressured into sterilizations

Drug repurposing or repositioning? The language matters

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Activists slam private health insurers over coverage restrictions

With measles on the rise, a personal story of a devastating disease

Dobbs anniversary: the lost opportunity of abortion as health care

Cue Health, Covid

Wikipedia

H5N1 virus can be tracked in retail milk, scientists say

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Listen: More tumult at BIO & coercive care for sickle cell patients

FDA poised to publish guidelines for clinical trial diversity

Data integrity in scientific journals requires "effort" by publishers, institutions

Solving academic medical centers' existential crisis

hotspot

entertainment

focus

Wikipedia